ZURICH, Feb 16 (Reuters) - Actelion said on Thursday that Johnson Johnson's agreed tender offer for the Swiss biotechnology company's shares is expected to start on March 3 and to run to March 30. The price is $280 per share, valuing Actelion at $30 billion. Shares of the new research and development company being spun out of Actelion for a Swiss listing will be distributed to Actelion shareholders as a stock dividend prior to settlement of tender offer, it said. (Reporting by John Miller; Editing by Michael Shields) Cmdr: Itâ€™s time to get Russia out of Americas White House!
Trump and ALL of his bunch have to go! 486